Overview

ALSENLITE: Senolytics for Alzheimer's Disease

Status:
Enrolling by invitation

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

Summary

This study is being done to evaluate the safety and feasibility of using Dasatinib and Quercetin together in subjects with Mild Cognitive Impairment (MCI) or Alzheimer's disease.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

James L. Kirkland, MD, PhD

Treatments:

Dasatinib
Quercetin